Crossroad Venture Capital Fund

What is Crossroad Venture Capital Fund?

Crossroad Venture Capital Fund, known as Crossroad, is a top-tier venture capital fund that specializes in early-stage and seed investment, focusing on Israeli companies. They primarily invest in enterprises with unique intellectual property, standout management teams, and a high potential for market penetration and growth.

Their investment realms include Medical Devices, Information & Communication Technology (ICT), Renewable Energy, Biotechnology, and Pharmaceuticals. By leveraging their unique strategic capabilities and a broad multinational network, their aim is to add significant value to the companies they invest in.

Crossroad has been active since 2010 and has invested over $100 million across 8 portfolio companies, demonstrating a commitment to fostering innovation and development in key technological and life sciences sectors.

Their portfolio features Robotemi, developing personal robotics; Hairstetics, inventing non-surgical baldness treatments; C.En for energy storage solutions; Regentis Biomaterials working on tissue repair; Mapi Pharma, specializing in pharmaceuticals; Pharma Two B, creating value-added drug combinations; Stem Cell Medicine, innovating in life sciences; and Roboteam, producers of tactical robotic systems.

They also showcase involvement in a range of events such as MWC 2019 and have secured funding and partnerships, reflecting active participation in their invested companies' growth and industry progress. The team is led by managing partners Boris Krasny and Itamar Borowitz, PhD, alongside investment managers Itay Attar, CPA, and Dudi Peru, CPA, MBA, all bringing a wealth of experience and expertise to the fund's operations.